Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 8, 2015, Pages 464-471

  Andrade Campos, Marcio M ^a,b   Montes Limón, Anel E ^a   Soro Alcubierre, Gloria ^a   Lievano, Paola ^a   López Gómez, Luis ^c   Baringo, Teresa ^a   Giraldo, Pilar ^a,b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c Royo Villanova Hospital   (Spain)

Author keywords

Elderly; Indolent NHL; Quality of life; Radioimmunotherapy; Safety

Indexed keywords

IBRITUMOMAB TIUXETAN; PEGFILGRASTIM; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; ESOPHAGUS CANCER; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GERIATRIC PATIENT; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MEDICAL OUTCOMES STUDY SHORT FORM 36; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONCOCYTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RECTUM CANCER; SECOND CANCER; SHORT FORM 36; SKIN CANCER; SOCIAL INTERACTION; SPAIN; SQUAMOUS CELL CARCINOMA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TIME TO PROGRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY;

EID: 84937813766     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.025     Document Type: Article

References (30)

1. Leukemia and Lymphoma Society. Facts 2012. Statistics Review. Available at: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmterial/generalcancer/pdf/facts.pdf. Accessed November 14, 2014.
2. J.L. Cultrera, and S.M. Dalia Diffuse large B-cell lymphoma: current strategies and future directions Cancer Control 19 2012 204 213
3. American Cancer Society Cancer Facts and Figures 2012 2012 American Cancer Society Atlanta, GA
4. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project Blood 89 1997 3909
5. R. Hoffman, B. Furie, E.J. Benz, and et al. Hematology: Basic Principles and Practice 5th ed 2009 Churchill Livingstone Philadelphia
6. P. Solal-Céligny, M. Bellei, L. Marcheselli, and et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database J Clin Oncol 30 2012 3848 3853
7. M. Dreyling, M. Ghielmini, R. Marcus on behalf of the ESMO Guidelines Working Group Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 suppl 3 2014 iii76 iii82
8. K. Izutsu Treatment of follicular lymphoma J Clin Exp Hematop 54 2014 31 37
9. A. Freedman Follicular lymphoma: 2014 update on diagnosis and management Am J Hematol 89 2014 429 436
10. C.A. Jacobson, and A.S. Freedman Early stage follicular lymphoma, current management and controversies Curr Opin Oncol 24 2012 475 479
11. M.P. MacManus, and R.T. Hoppe Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University J Clin Oncol 14 1996 1282 1290
12. O.W. Press Review of radiolabeled antibody therapy of B-cell lymphomas Semin Oncol 26 5 suppl 14 1999 58 65
13. T. Illidge, and F. Morschhauser Radioimmunotherapy in follicular lymphoma Best Pract Res Clin Haematol 24 2011 279 293
14. T.E. Witzig, L.I. Gordon, F. Cabanillas, and et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463
15. F. Morschhauser, J. Radford, A. Van Hoof, and et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 2008 5156 5164
16. F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence Oncologist 14 suppl 2 2009 17 29
17. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial J Clin Oncol 31 2013 1977 1983
18. J. Alonso, L. Prieto, and J.M. Antó La versión española del SF-36 health survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados Med Clin (Barc) 104 1995 771 776
19. G. Costa-Requena, and F. Gil Quality of life in the chemotherapy treatment of Spanish cancer patients: a comparison of general population norms Psychooncology 18 2009 1053 1059
20. J. Herce-Lopez, A. Rollon-Mayordomo, R. Lozano-Rosado, P. Infante-Cossio, and C.I. Salazar-Fernandez Assessment of quality of life of oral cancer survivors compared with Spanish populations norms Int J Oral Maxillofac Surg 42 2013 446 452
21. A.J. Ambinder, P.J. Shenoy, N. Malik, and et al. Exploring risk factors for follicular lymphoma Adv Hematol 2012 2012 626035
22. G. Salles, J.F. Seymour, F. Offner, and et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Lancet 377 2011 42 51
23. K. Hohloch, A.B. Delaloye, C. Windemuth-Kieselbach, and et al. Radioimmunotherapy confers long-term survival for lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network J Nucl Med 90 2011 1307 1315
24. N. Uike, I. Choi, M. Tsuda, and et al. Factors associated with effects of (90)Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era Int J Hematol 100 2014 386 392
25. L. Lowry, and K.M. Ardeshna Has single-agent rituximab replaced watch-and-wait for patient with asymptomatic low-grade follicular lymphoma? Cancer J 18 2012 390 395
26. K. Ardeshna, P. Smith, A. Norton, and et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial Lancet 362 2003 516 522
27. Ardeshna KM, Qian W, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): a preliminary analysis. Paper presented at: 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, CA; abstract 6, plenary session. Available at: https://ash.confex.com/ash/2010/webprogram/Paper27692.html. Accessed November 14, 2014.
28. M.M. Andrade Campos, A.E. Montes Limón, J.M. Grasa, and et al. RIT with Y90-ibritumomab tiuxetan in follicular non-Hodgkin lymphoma: evaluation of recent outcomes in a single institution J Oncol 2012 2012 41274
29. F. Buchegger, C. Antonescu, C. Help, and et al. Six of 12 relapsed refractory indolent lymphoma patients treated 10 years ago with 131-I-tositumomab remain in complete remission J Nucl Med 52 2011 896 900
30. 90Y-ibritumomab tiuxetan in patients with mantle cell lymphoma: results of a multicenter, phase 2 pilot trial from the GELTAMO group Haematologica 98 2013 1563 1570